A comparative study between cleavage stage embryo transfer at day 3 and blastocyst stage transfer at day 5 in *in-vitro* fertilization/intra-cytoplasmic sperm injection on clinical pregnancy rates

**ABSTRACT**

**OBJECTIVE:** To evaluate the efficacy of blastocyst transfer in comparison with cleavage stage transfer. **STUDY DESIGN:** A randomized, prospective study was conducted in Infertility clinic, Department of Obstetrics and Gynecology, Mahatma Gandhi Medical College and Hospital, Jaipur on 300 patients aged 25-40 years undergoing *in-vitro* fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) cycle from May 2010-April 2011. When three or more Grade-I embryos were observed on day 2 of culture, patients were divided randomly into two study groups, cleavage stage transfer and blastocyst transfer group having 150 patients each. Primary outcomes evaluated were, Clinical pregnancy rate and Implantation rate. The results were analyzed using proportions, standard deviation and Chi-square test. **RESULTS:** Both the groups were similar for age, indication and number of embryos transferred. Clinical pregnancies after blastocyst transfer were significantly higher 66 (44.0%) compared to cleavage stage embryo transfer 44 (29.33%) ($P<0.01$). Implantation rate for blastocyst transfer group was also significantly higher ($P<0.001$). **CONCLUSION:** Blastocyst transfer having higher implantation rate and clinical pregnancy rate lead to reduction in multiple pregnancies.

**KEY WORDS:** Blastocyst transfer, clinical pregnancy rates, embryo transfer, intra-cytoplasmic sperm injection, *in-vitro* fertilization

**INTRODUCTION**

Advances in the dynamics of embryo culture allow us to culture embryos to the blastocyst stage. Prolonging the duration of culture to day 5 allows chromosomally competent embryos to develop to the blastocyst stage and permits selection of embryos that have the potential for continued development under embryonic genomic control.[1] In addition, selection of day 5 embryos has the advantage of physiological synchronization with the uterine endometrium, thereby resulting in better implantation rates.[2] The introduction of sequential media that takes into account the changing metabolic requirement of the embryo, as it develops from the zygote to the blastocyst stage, allows extended culture.[3,4] Blastocyst transfer should enable transfer of fewer, but higher quality embryos resulting in increased implantation rates. This would maintain a high pregnancy rate while controlling the multiple pregnancy rates.[5] Reasons for higher success rates with blastocysts are mainly related to embryo selection process. Embryos selected for transfer on day 5 are healthier and carry a lower risk of being aneuploid, thereby increasing patients' chance of achieving an on-going pregnancy.[6]

Although blastocyst transfer has been shown to be beneficial in good prognosis patients, similar benefits were not seen in an unselected group. The aim of our study was to evaluate the efficacy of blastocyst transfer in comparison with day 3 embryo transfer.

**MATERIALS AND METHODS**

Three hundred patients aged 25-40 years undergoing *in-vitro* fertilization (IVF)/
intra–cytoplasmic sperm injection (ICSI) cycle between May 2010 and April 2011 were included in our study, meeting the inclusion criteria set namely, 2-20 years of infertility, having minimum five oocytes at oocyte pick up and endometrial thickness of 7 mm and more indicating good ovarian response, having normal uterine cavity and basal follicle stimulating hormone level (FSH < 10 mIU/ml). Complete patient work-up, baseline routine investigations, and hormonal analysis were done, and postmenstrual diagnostic hysteroscopy was done. Patient was put on long protocol, gonadotropin-releasing hormone agonists started on cycle day 21 daily doses given subcutaneously till cycle day 3. Hormonal evaluation–serum FSH, luteinizing hormone, estradiol (E2) and transvaginal sonography was done on day 3 to confirm down-regulation. Induction with recombinant FSH (rFSH) was started once pituitary down-regulation was confirmed. The dose schedule was modified according to parameters such as body mass index, previous response, and ovarian reserve estimates and was given for 5 days (days 3-7). Follicular monitoring was initiated on day 8 of the cycle, and further dose of rFSH was given according to follicle size and continued till day 11. Patients were scheduled for oocyte retrieval once at least 3 follicles reached 18 mm size and injection human chorionic gonadotropin (hCG) 10,000 IU was given. Transvaginal sonography guided oocyte retrieval was then planned 36 h after hCG, which was performed under short general anesthesia.

The retrieved oocytes were then incubated for 3-4 h in IVF-30 media and then depending on maturity of oocytes and previous IVF performance, IVF or ICSI was performed. Short incubation insemination for 2 h and group culture was followed for IVF.

Denudation of oocytes was carried out before ICSI was performed. Oocytes were incubated overnight in IVF-30 media in a carbon dioxide incubator and observed after 16-18 h postinsemination for fertilization. The fertilized oocytes were then transferred into a cleavage medium and incubated. Embryos were observed on day 2 and transfer was scheduled according to random allocation of patients into two groups based on availability of minimum three good quality embryos:

Group 1: Included patients undergoing embryo transfer on day 3, and Group 2 in which extended culture till day 5 was done in G2 plus media and blastocyst was transferred on day 5.

Random allocation of patients was done equally so that study population in both groups was comparable. The number of blastocysts/embryos transferred was determined by the availability of embryos, patients’ age and previous clinical history. Not more than three embryos/blastocysts were transferred on any occasion. All transfers were performed using Edward–Wallace catheter. Luteal support was given in the form of micronized vaginal progesterone in dose of 200 mg thrice a day for 18 days postretrieval. In addition, injection hCG 2000 IU was given intramuscular on days 5th, 8th, and 11th after retrieval. Serum beta-hCG was performed on day 15 following embryo transfer, and if positive then transvaginal sonography was performed 15 days later to detect and confirm intra-uterine pregnancy. Positive cases were followed till 6 weeks to check for fetal cardiac activity.

**Outcome measures**

**Primary outcome**
- Implantation rate
- Clinical pregnancy rate.

**Secondary outcome**
- Fertilization rate
- Cleavage rate
- Multiple pregnancy rates
- Mean number of embryos/blastocysts transferred.

**Implantation rate**
The implantation rate is usually defined as the percentage of embryos transferred that implants and develops to the stage of ultrasound documented fetal heartbeat.

**Clinical pregnancy**
defined as the presence of the gestational sac with a fetal pole with cardiac activity on transvaginal ultrasound at 6 weeks.

**Fertilization rate**
It is the percentage of eggs fertilized out of eggs inseminated or injected.

**Cleavage rate**
total number of day 3 embryos by total number of fertilized oocytes.

**Study analysis**
The results were analyzed using proportions, standard deviation, and Chi-square test.

**RESULTS**
A total of 300 patients was randomized for the study and allocated into two groups each of 150 patients. As shown in Table 1, no significant difference was found for age, duration of infertility, type of infertility, ratio of ICSI: IVF cases, and mean E2 level at hCG injection. Table 2 shows that no significant difference between both the study groups in terms of indication for IVF.
As shown in Table 3, both the groups had a comparable mean number of oocytes at the retrieval, same proportion of mature oocytes and fertilized oocytes, and a comparable mean number of embryos per transfer.

Table 4 shows higher clinical pregnancies per oocyte retrieval was observed in blastocyst transfer group than in day 3 embryo transfer group (44% and 29.33%) (*P < 0.01*), and higher implantation rate per embryo transfer in blastocyst transfer group (35.17%) than in day 3 embryo transfer group (21.35%) (*P < 0.01*).

Table 5 shows that although multiple pregnancy rate in blastocyst transfer group were higher than day 3 embryo transfer group, association was not significant (48.48% and 31.81%) (*P > 0.05*). Pregnancy rate in blastocyst transfer group was significantly higher than day 3 embryo transfer group (44% and 29.33%). Day 3 embryo transfer group reported 2% of pregnancies as missed abortions and 1% as ectopic while day 5 blastocyst transfer group had no ectopic pregnancy and 1.33% pregnancies ended up as missed abortions.

Hence, women in blastocyst transfer group had significantly higher clinical pregnancy rates, implantation rate, and cleavage rates.

**DISCUSSION**

Blastocyst transfer is gaining popularity, now-a-days due to its higher clinical pregnancy rates and implantation rates. In this study, no significant difference was found between the two groups.

---

**Table 1: Demographic profile**

| Variable                      | Day 3 transfer (n=150) | Day 5 transfer (n=150) |
|-------------------------------|------------------------|------------------------|
| Age (years, mean±SD)         | 32.46±4.3              | 32.04±4.4              |
| Range                        | 25-40                  | 25-40                  |
| Duration of infertility (years) | 8.9±5.2              | 7.7±4.7                |
| Type of infertility          |                        |                        |
| Primary                      | 101                    | 100                    |
| Secondary                    | 49                     | 50                     |
| Number of cases with ICSI    | 46                     | 55                     |
| Number of cases with IVF     | 104                    | 95                     |
| Estradiol at hCG injection (pg/ml, mean±SD) | 1158.3±890.2 | 1327.52±917.62 |

**Table 2: Clinical profile of patients**

| Infertility indication (n)   | Day 3 transfer (n=150) | Day 5 transfer (n=150) |
|------------------------------|------------------------|------------------------|
| Tubal                        | 53                     | 42                     |
| Endometriosis                | 10                     | 9                      |
| Anovulation                  | 15                     | 21                     |
| Male                         | 42                     | 44                     |
| Mixed                        | 15                     | 19                     |
| Unexplained                  | 15                     | 15                     |

**Table 3: Results after oocyte aspiration with respect to the number of oocytes and embryos**

| Variable                      | Day 3 transfer (n=150) | Day 5 transfer (n=150) |
|-------------------------------|------------------------|------------------------|
| Oocytes at OR (n)             | 1094                   | 1141                   |
| Mature oocytes (n)            | 922                    | 1007                   |
| Fertilized oocytes (n)        | 599                    | 658                    |
| Total day 3 embryos (n)       | 447                    | 549                    |
| Embryos transferred (n)       | 309                    | 290                    |
| Number of oocytes at OR (mean±SD) | 7.3±2.1          | 7.6±2.3                |
| Number of mature oocytes (mean±SD) | 6.1±1.6              | 6.6±2.1                |
| Number of two-pronucleate embryos (mean±SD) | 3.9±1.7              | 4.3±1.5                |
| Number of embryos per transfer (mean±SD) | 2.04±0.74           | 1.93±0.48              |
| Fertilization rate (%)        | 64.96                  | 65.34 (*P<0.05*) NS    |
| Cleavage rate (%)             | 74.62                  | 83.43 (*P<0.001) HS    |

**Table 4: Results after oocyte aspiration with respect to outcome**

| Variable                      | Day 3 transfer (n=150) | Day 5 transfer (n=150) | χ²  | df | P    |
|-------------------------------|------------------------|------------------------|-----|----|------|
| Positive beta-hCG             | 48                     | 68                     |     |    |      |
| Percentage of per OR          | 32                     | 45.33                  | 5.6 | 1  | <0.01 (S) |
| Clinical pregnancies (n)      | 44                     | 66                     |     |    |      |
| Clinical pregnancy rate (%)   | 29.33                  | 44                     | 6.3 | 1  | <0.01 (S) |
| Embryos transferred (n)       | 309                    | 290                    |     |    |      |
| Total gestational sacs on USG (n) | 66                   | 102                    |     |    |      |
| Implantation rate             | 21.35                  | 35.17                  | 14.12 | 1  | <0.001 (HS) |
| Multiple pregnancies          | 14                     | 32                     |     |    |      |
| Multiple pregnancy rates      | 31.81                  | 48.48                  | 2.36 | 1  | <0.05 (NS)  |

**Table 5: Pregnancy outcome**

| Variable                      | Day 3 transfer (n=150) (%) | Day 5 transfer (n=150) (%) |
|-------------------------------|----------------------------|----------------------------|
| Positive beta-hCG             | 48                         | 68                         |
| Clinical pregnancies          | 44 (29.33)                 | 66 (44)                    |
| Missed                        | 3 (2)                      | 2 (1.33)                   |
| Ectopic                      | 1 (0.66)                   | 0                          |
| Single                       | 30                         | 34                         |
| Twin                         | 10                         | 30                         |
| Triplets                     | 4                          | 2                          |

**Table 5**: Pregnancy outcome

| Variable                      | Day 3 transfer (n=150) (%) | Day 5 transfer (n=150) (%) |
|-------------------------------|----------------------------|----------------------------|
| Positive beta-hCG             | 48                         | 68                         |
| Clinical pregnancies          | 44 (29.33)                 | 66 (44)                    |
| Missed                        | 3 (2)                      | 2 (1.33)                   |
| Ectopic                      | 1 (0.66)                   | 0                          |
| Single                       | 30                         | 34                         |
| Twin                         | 10                         | 30                         |
| Triplets                     | 4                          | 2                          |
both the study groups in terms of age, duration of infertility, indication of infertility, and type of infertility. This was in agreement with the study conducted by Van der Auwera et al. The mean number of embryos transferred in both groups showed no significant difference (2.04 and 1.93, \( P > 0.05 \)).

In our study, the proportion of clinical pregnancies occurring as a result of blastocyst transfer was higher 66 (44%) as compared to cleavage stage embryo transfer which was 45 (30%), the association was statistically significant and similar results were seen in the study by Van der Auwera et al. and Mangalraj et al. Although the fertilization rate was higher with blastocyst transfer (65.34%) compared to day 3 embryo transfer (64.96%) in our study, but association was not significant (\( P < 0.05 \)) and same association was observed in the study of Mangalraj et al.

Among both the study groups, cleavage rate (74.62% and 83.43%) and implantation rate (21.35% and 35.17%) were significantly higher in blastocyst transfer/group 2 over day 3 embryo transfer/group 1. The results of our study were similar to the study by Van der Auwera et al. and Mangalraj et al. Although the proportion of multiple pregnancies in our study was higher with blastocyst transfer (48.48%) than with embryo transfer (31.81%), but the association was not significant (\( P > 0.05 \)).

Thus, in younger women with good ovarian response and three or more grade-I embryos on day 3, extended culture can be offered. The good clinical pregnancy and implantation rates observed will confidently allow transfer of not more than two good quality blastocysts and allow women to enjoy the benefits of limiting numbers for transfer.

CONCLUSION

This study has shown that in younger patients with good ovarian response extended culture to day 5 can be offered as blastocyst transfer is found to have good clinical pregnancy rates. The good clinical pregnancy and implantation rates observed will confidently allow transfer of not more than two good quality blastocysts and allow women to enjoy the benefits of limiting numbers for transfer.

REFERENCES

1. Racowsky C, Jackson KV, Cekleniak NA, Fox JH, Hornstein MD, Ginsburg ES. The number of eight-cell embryos is a key determinant for selecting day 3 or day 5 transfer. Fertil Steril 2000;73:558-64.
2. Alper MM, Brinsden P, Fischer R, Wikland M. To blastocyst or not to blastocyst? That is the question. Hum Reprod 2001;16:617-9.
3. de los Santos MJ, Mercader A, Galán A, Albert C, Romero JL, Pellicer A. Implantation rates after two, three, or five days of embryo culture. Placenta 2003;24 Suppl B: S13-9.
4. Gardner DK, Surrey E, Minjarez D, Leitz A, Stevens J, Schoolcraft WB. Single blastocyst transfer: A prospective randomized trial. Fertil Steril 2004;81:551-5.
5. Kolibianakis EM, Zikopoulus K, Verpoest W, Camus M, Joris H, Van Steirteghem AC, et al. Should we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer? Hum Reprod 2004;19:2550-4.
6. Papanikolaou EG, Camus M, Kolibianakis EM, Van Landuyt L, Van Steirteghem A, Devroey P. In vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos. N Engl J Med 2006;354:1139-46.
7. Van der Auwera I, Debrock S, Spiessens C, Afschrift H, Bakelants E, Meuleman C, et al. A prospective randomized study: Day 2 versus day 5 embryo transfer. Hum Reprod 2002;17:1507-12.
8. Mangalraj AM, Muthukumar K, Aleyamma T, Kamath MS, George K. Blastocyst stage transfer vs cleavage stage embryo transfer. J Hum Reprod Sci 2009;2:23-6.

How to cite this article: Kaur P, Swarankar ML, Maheshwari M, Acharya V. A comparative study between cleavage stage embryo transfer at day 3 and blastocyst stage transfer at day 5 in in-vitro fertilization/intra-cytoplasmic sperm injection on clinical pregnancy rates. J Hum Reprod Sci 2014;7:194-7.

Source of Support: Nil, Conflict of Interest: None declared.